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ABSTRACT The cyclin-dependent kinases are key cell
cycle regulators whose activation is required for passage from
one cell cyde phase to the next. In mammalian cells, CDK2 has
been implicated in control ofthe G, and S phases. We have used
a two-hybrid protein interaction screen to identify cDNAs
encoding proteins that can interact with CDK2. Among those
identified was a protein (KAP), which contained the HCXX-
XXGR motif characteristic of protein tyrosine phosphatases.
KAP showed phosphatase activity toward substrates contain-
ing either phosphotyrosine or phosphoserine residues. Since
KAP is not significantly similar to known phosphatases beyond
the catalytic core motif, it represents an additional class of dual
specificity phosphatase. KAP interacted with cdc2 and CDK2
in yeast. In mammalian cells, KAP also associated with cdc2
and CDK2 but showed a preference for cdc2. The ability of
KAP to bind multiple cyclin-dependent kinases suggests that it
may play a role in cell cycle regulation.
In fission and budding yeasts, control of both the G1/S and
G2/M transitions is accomplished through the activity of a
single cycin-dependent kinase known as cdc2 in Schizosac-
charomyces pombe or CDC28 in Saccharomyces cerevisiae
(reviewed in ref. 1). In mammalian cells, the cyclin-
dependent kinase family consists of at least five members:
cdc2 (CDK1) and CDK2-CDK5 (refs. 2-4; reviewed in ref.
1). These associate with an equally diverse family of positive
regulatory subunits known as cyclins, and each cyclin-CDK
complex may play a distinct role in cell cycle regulation (see
ref. 5 for a recent review).
Several lines ofevidence suggest that CDK2 participates in
control ofthe G1 and S phases. First, microinjection ofCDK2
antibodies into mammalian cells caused cell cycle arrest prior
to S phase (6, 7). Second, CDK2 complexes with cyclins that
act early in the cell cycle-namely, cycins A, D, and E (2,
4, 8). Of these, cyclins D and E have demonstrated roles in
the control of G1 (9, 10). Cyclin A executes at least one of its
functions during S phase as indicated both by its periodic
expression and by the results of antibody microinjection
experiments (11, 12). Numerous studies have suggested that
passage through G2 and M is regulated by a different cycin-
dependent kinase, cdc2, and its associated cyclins A and B
(reviewed in refs. 13-15).
Coimmunoprecipitation experiments have revealed that
cyclin-dependent kinases bind a number of proteins in addi-
tion to cyclins. For example, cdc2/cyclin B forms a stable
complex with cdc25, a dual-specificity phosphatase that
regulates cdc2 activity (16). Also, proliferating cell nuclear
antigen and a protein known as p21 are universal components
of cell cycle kinase complexes (4, 17). On the premise that
proteins that associate with cycin-dependent kinases are
likely to function in cell cycle regulation, we have used the
two-hybrid screen (18) to isolate cDNAs encoding proteins
that can interact with CDK2. Among the proteins identified
by this procedure was a previously uncharacterized dual-
specificity protein phosphatase, which we have termed KAP.
KAP binds to cdc2 and CDK2 in mammalian cells, suggesting
that it may play a role in cell cycle control.§
MATERIALS AND METHODS
Construction of cDNA Libraries and Two-Hybrid Screens.
Construction of the HeLa cell cDNA library and two-hybrid
screening were exactly as described (19).
Primary positives were tested for target specificity by
retransformation of library plasmids into the tester strain in
conjunction with a number of different GAL4 DNA binding
domain-target fusions. These included fusions with cdc2,
CDK2, CDK4, CDK5, SNF1, and piml. The SNF1 fusion
was a gift from Stan Fields, State University of New York,
Stony Brook; the CDK4 plasmid was provided by Yue Xiong,
Cold Spring Harbor Laboratory; the CDK5 fusion was pro-
vided by Hui Zhang, Cold Spring Harbor Laboratory; and the
piml fusion was a gift from Harriet Feilotter, Cold Spring
Harbor Laboratory.
Phosphatase Assays. The entire coding sequence of the
KAP cDNA was inserted into the bacterial expression vector
pGEX-KG to form a plasmid that directed the expression of
a fusion between glutathione S-transferase (GST) and KAP
(pGST-KAPw). We also constructed a similar plasmid en-
coding a fusion between GST and a mutant KAP protein in
which Cys-139 had been changed to Ser (pGST-KAPm).
These plasmids were transformed into Escherichia coli BL21
for fusion protein expression. Cells containing each plasmid
were grown at 370C to a density of OD600 = 0.5; the cultures
were then shifted to 230C-250C, and isopropyl P-D-
thiogalactopyranoside was added to 0.4 mM. After 12-14 hr,
cells were harvested, washed once in phosphate-buffered
saline, and resuspended in GCB [50 mM TrisHCl, pH
8.0/200 mM NaCl/1 mM EDTA, 1% Triton X-100/1 mM
dithiothreitol (DTT)/1 x protease inhibitors (2 ,g of leupep-
tin per ml/2 ,ug of aprotinin per ml/0.3 ,.g of benzamide per
ml/10 yg of soybean trypsin inhibitor per ml/100 /Ag of
L-1-tosylamido-2-phenylethyl chloromethyl ketone per ml/50
,ug of 7-amino-1-chloro-3-tosylamido-2-heptanone per ml)].
Cells were lysed by sonication and fusion proteins were
prepared as described (19).
Preparation of phosphatase substrates and phosphatase
assays were essentially as described (20). For phosphoty-
rosine dephosphorylation, a standard assay included 3-6 ,ug
Abbreviations: GST, glutathione S-transferase; RCML, reduced
carboxyamidomethylated and maleylated lysozyme; HA, hemagglu-
tinin.
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FIG. 1. Interaction of KAP
with cdc2 and CDK2 in yeast. A
yeast strain containing a GAL4-
dependent HIS3 gene was trans-
formed with a plasmid encoding a
fusion between the GAL4 activa-
tion domain and KAP. This strain
was simultaneously transformed
SNF with plasmids encoding fusions
between the GAL4 DNA binding
domain and cdc2, CDK2, CDK4,
CDK5, or SNF1 (as indicated).
Transformants were restreaked on
plates lacking leucine and tryp-
tophan (+ histidine) or lacking
leucine, tryptophan, and histidine
(- histidine).
of GST-KAPw or GST-KAPm in 60 ,ul containing 2 ,tM
[32P]tyrosine reduced carboxyamidomethylated and maley-
lated lysozyme (RCML), 0.1 mg ofbovine serum albumin per
ml, 2 mM DTT, and 50 mM 2-(N-morpholino)ethanesulfonic
acid (pH 6.5). Phosphoserine dephosphorylation reactions
using 2 ,M [32P]serine RCML required a 10-fold higher
concentration of GST-KAPw or GST-KAPm and were car-
ried out at pH 6.0. Reactions were started by the addition of
enzyme and terminated after 10 min (unless otherwise indi-
cated) by the addition of290 ,ul of stop solution [0.9M HCl/90
mM Na4P207/2 mM NaH2PO4/1-2% (vol/vol) Celite/6%
(vol/vol) Norit-A charcoal]. The phosphorylated substrate
bound to the charcoal and was removed by centrifugation.
Released phosphate was measured by scintillation counting
of the supernatant. In all cases, a similarly treated reaction
mixture lacking enzyme served as a blank. For testing the
effects of inhibitors, reactions proceeded for 10 min in the
presence of 1 mM Na3VO4/1 ,M okadaic acid/1 mM tetra-
mizole/5 mM sodium tartrate/1 mM EDTA/1 mM EGTA, or
1 mM NaF. N-Ethylmaleimide (10 mM) and iodoacetic acid
(10 mM) were preincubated with the enzyme for 5 min at
300C.
Transfection, Immunoprecipitation, and Western Blotting.
For use in transfection experiments, we constructed a KAP
cDNA in which three copies of the hemagglutinin epitope tag
(HA; ref. 21) were inserted at amino acid 3 of the KAP
sequence. This modified KAP cDNA was inserted down-
stream of the cytomegalovirus promoter in the expression
vector pCMV5 (22) to form the plasmid pCMV-HA-KAP.
COS-1 cells were grown to confluence and then transfected
with this construct (3 jig of DNA per 6-cm plate) using
lipofectamine (BRL) according to the manufacturer's instruc-
tions. At 48 hr posttransfection, cells were metabolically
labeled with [35S]methionine. Proteins were immunoprecip-
itated from cell lysates with 1 ,ul of anti-HA (12CA5, Babco,
Emeryville, CA), 1 ,ul of anti-cdc2 (G6; ref. 23), or 1 ,l of
anti-CDK2 (K. Galaktionov, personal communication) anti-
body as described (4). Proteins were released from the
Sepharose by boiling in SDS sample buffer and were elec-
trophoresed on a 12.5% polyacrylamide gel. Western blotting
and partial proteolytic mapping were performed exactly as
described (4).
RESULTS AND DISCUSSION
Isolation of CDK2 Binding Proteins. To search for previ-
ously uncharacterized proteins with a role in cell cycle
regulation, we have used a two-hybrid screen (18, 24) to
isolate cDNAs encoding proteins that can physically interact
with CDK2 (19). Using this procedure, we isolated three
classes of cDNAs. The first encoded a previously character-
ized protein known as CKS1 (25). CKS1 is a human homolog
of fission yeast pl3sucl, a protein that binds to fission yeast
cdc2. The second corresponded to the adenovirus E1A-
associated p130, a newly discovered member of the RB gene
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MetLysPro
61 CCCAGTTCAATACAAACAAGTGAGTTTGACTCATCAGATGAAGAGCCTATTGAAGATGAA
4 ProSerSerIleGlnThrSerGluPheAspSerSerAspGluGluProIleGluAspGlu
121 CAGACTCCAATTCATATATCATGGCTATCTTTGTCACGAGTGAATTGTTCTCAGTTTCTC
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181 GGTTTATGTGCTCTTCCAGGTTGTAAATTTAAAGATGTTAGAAGAAATGTCCAAAAAGAT
44 GlyLeuCysAlaLeuProGlyCysLysPheLysAspValArgArgAsnValGlnLysAsp
241 ACAGAAGAACTAAAGAGCTGTGGTATACAAGACATATTTGTTTTCTGCACCAGAGGGGAA
64 ThrGluGluLeuLysSerCysGlyIleGlnAspIlePheValPheCysThrArgGlyGlu
301 CTGTCAAAATATAGAGTCCCAAACCTTCTGGATCTCTACCAGCAATGTGGAATTATCACC
84 LeuSerLysTyrArgValProAsnLeuLeuAspLeuTyrGlGllnCysGlyIleIleThr
361 CATCATCATCCAATCGCAGATGGAGGGACTCCTGACATAGCCAGCTGCTGTGAAATAATG
104 HisHisHisProIleAlaAspGlyGlyThrProAspIleAlaSerCysCysGluIleMet
421 GAAGAGCTTACAACCTGCCTTAAAAATTACCGAAAAACCTTAATACACTGCTATGGAGGA
124 GluGluLeuThrThrCysLeuLysAsnTyrArgLysThrLeuIleHisCysTyrGlyGly
481 CTTGGGAGATCTTGTCTTGTAGCTGCTTGTCTCCTACTATACCTGTCTGACACAATATCA
144 LeuGlyArgSerCysLeuValAlaAlaCysLeuLeuLeuTyrLeuSerAspThrIleSer
541 CCAGAGCAAGCCATAGACAGCCTGCGAGACCTAAGAGGATCCGGGGCAATACAGACCATC
164 ProGluGlnAlaIleAspSerLeuArgAspLeuArgGlySerGlyAlaIleGlnThrIle
601 AAGCAATACAATTATCTTCATGAGTTTCGGGACAAATTAGCTGCACATCTATCATCAAGA
184 LysGlnTyrAsnTyrLeuHisGluPheArgAspLysLeuAlaAlaHisLeuSerSerArg
661 GATTCACAATCAAGATCTGTATCAAGATAAAGGAATTCAAATAGCATATATATGACCATG
204 AspSerGlnSerArgSerValSerArgEnd
721 TCTGAAATGTCAGTTCTCTAGCATAATTTGTATTGAAATGAAACCACCAGTGTTATCAAC
781 TTGAATGTAAATGTACATGTGCAGATATTCCTAAAGTTTTATTGACAAAAAAAAAAAAAA
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FIG. 2. Sequence ofKAP. (A) Complete sequence ofKAP cDNA
and deduced amino acid sequence of KAP protein are shown. The
HCXXXXGR motif characteristic of protein tyrosine phosphatases
is underlined. (B) Region surrounding the HCXXXXGR motif in
KAP is aligned with the analogous region from a number of other
phosphatases. These are VH1 (vaccinia virus), 3CH134(MKP) (hu-
man), VHR (human), BVP (baculovirus Autographa californica),
YVH1 (S. cerevisiae), IphP (cyanobacterium Nostoc commune
UTEX 584), HCDC25A (human), and PTP-1B (human) (16, 20,
26-32). Amino acids conserved among all of these proteins are
boxed.
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family (19). The third class, described here, encoded a dual
specificity protein phosphatase, which we have designated
KAP (CDK associated phosphatase; see below). This protein
was capable of interacting in yeast either with CDK2 or with
human cdc2 but not with CDK4, CDK5, S. cerevisiae SNF1
kinase, or Sc. pombe pimil (Fig. 1; data not shown).
The complete sequence ofthe KAPcDNA and the deduced
amino acid sequence of the KAP protein are shown in Fig.
2A. Two lines of evidence suggest that we have identified the
complete KAP open reading frame. First, Northern blot
analysis indicated that the KAP mRNA was approximately
equal in size to the KAP cDNA that we had isolated (un-
published results). Second, we have raised a polyclonal
antiserum specific for KAP, and this serum recognized in cell
lysates a protein that roughly comigrated with KAP protein
produced by in vitro translation of our cDNA (unpublished
results).
Searches of available data bases failed to identify signifi-
cant similarity between KAP and any previously character-
ized protein. However, the KAP sequence was found to
contain a motif, HCXXXXGR, characteristic of the catalytic
core of protein tyrosine phosphatases (see below; reviewed
in refs. 33 and 34; see Fig. 2).
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KAP Is a Dual Specificity Phosphatase. To determine
whether KAP was, in fact, a protein tyrosine phosphatase,
the entire KAP protein was produced in bacteria as a fusion
with GST and tested for activity against a model tyrosine
phosphatase. substrate, tyrosine phosphorylated RCML.
Upon treatment of [32P]tyrosine RCML with KAP, a sub-
stantial release of phosphate was detected (Fig. 3A). KAP
tyrosine phosphatase activity was dependent on both enzyme
concentration and time for the first 10 min of the reaction.
Tyrosine dephosphorylation showed a sharp pH optimum
around pH 6.5; virtually no activity was seen above pH 7.0
or below pH 6.0 (unpublished results). Phosphatase activity
was sensitive to orthovanadate, a known inhibitor of protein
tyrosine phosphatases, but it was not affected by inhibitors of
acid phosphatase (tartrate), phosphatase 1A (okadaic acid),
alkaline phosphatase (tetramizole), or the general serine/
threonine phosphatase inhibitor fluoride (Fig. 3B). The
HCXXXXGR motif forms the catalytic core of protein tyro-
sine phosphatases, and the cysteine present in this motif is
directly involved in the dephosphorylation reaction, forming
a thiolphosphate intermediate (see refs. 33 and 34). Thus,
modification or mutation of this cysteine abolishes the ac-
tivity of known tyrosine phosphatases. Consistent with the
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FIG. 3. KAP is a dual-specificity protein phosphatase. (A) Bacterially produced GST-KAPw or a mutant GST-KAPm (C139S) was used
to dephosphorylate a model tyrosine phosphatase substrate RCML phosphorylated on tyrosine (20). Time course of the reaction is shown. (B)
Several known phosphatase inhibitors (V04, Na3VO4; OA, okadaic acid; Tart, tartrate; Tet, tetramizole; NEM, N-ethylmaleimide; IAA,
iodoacetic acid) were tested for their effect on the ability of GST-KAP to dephosphorylate tyrosine phosphorylated RCML. Activity in the
presence of inhibitors is expressed as percentage of control. (C and D) Same asA andB except that a model serine phosphatase substrate, serine
phosphorylated RCML, was used. Preparation of phosphatase substrates was essentially as described (20).
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notion that KAP acts through a similar catalytic mechanism,
treatment ofKAP with sulfhydryl modifying reagents, N-eth-
ylmaleimide or iodoacetic acid, abolished KAP activity (Fig.
3B). Furthermore, mutation of the putative catalytic cysteine
to serine (C139S) resulted in an inactive enzyme (Fig. 3A).
Several members of the tyrosine phosphatase family can
dephosphorylate not only phosphotyrosyl but also phos-
phoseryl and phosphothreonyl residues (26, 27, 35-37). To
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determine whether KAP was a member of this group of
dual-specificity phosphatases, we tested its ability to dephos-
phorylate phosphoseryl RCML. As shown in Fig. 3C, GST-
KAP showed significant activity toward this substrate. Ap-
proximately 10-fold more KAP enzyme was required to
achieve phosphate release from phosphoseryl RCML, which
equaled that seen with the phosphotyrosyl substrate. Such
differences in activity toward model substrates have previ-
ously been observed for other dual specificity phosphatases
(see ref. 36, for example). These probably do not reflect
differences in the intrinsic ability of the enzymes to dephos-
phorylate phosphoserine versus phosphotyrosine residues
but instead likely reflect the ability of the enzyme to recog-
nize phosphorylated residues in different contexts within
artificial substrates. The serine phosphatase activity of KAP
showed a spectrum of sensitivity to inhibitors identical to that
observed for its tyrosine phosphatase activity (Fig. 3D).
Also, mutation of Cys-139 abolished activity, suggesting that
dephosphorylation of phosphotyrosine and phosphoserine
proceeds through a similar mechanism (Fig. 3C).
Based on these results, we conclude that KAP is a dual-
specificity phosphatase. A detailed comparison of the se-
quence of KAP to known phosphatases revealed no signifi-
cant homology beyond the HCXXXXGR motif (Fig. 2B).
Thus, KAP represents an additional class of dual-specificity
phosphatase within the tyrosine phosphatase family.
KAP Associates with cdc2 and CDK2 in Ma Cells.
KAP interacted both with CDK2 and with cdc2 in yeast (Fig.
1). To ask whether KAP also associated with these proteins
in mammalian cells, we expressed in COS cells aKAP protein
bearing three copies of the HA epitope tag at its N terminus
(HA-KAP). In anti-HA immunoprecipitates from metaboli-
cally labeled, transfected cells, we observed a doublet cor-
responding to the epitope-tagged KAP protein and a promi-
nent band of -34 kDa, which roughly comigrated with cdc2
and CDK2 immunoprecipitated from lysates of the same
transfected cells (Fig. 4A). Similar bands were not observed
in anti-HA immunoprecipitates from untransfected cells or
from cells transfected with a control plasmid (unpublished
results). The interaction of KAP with cyclin-dependent ki-
nases in the two-hybrid screen suggested the possibility that
k H /
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FiG. 4. Interaction of KAP with cdc2 in mammalian cells. (A)
COS cells were transfected with a plasmid directing the expression
of a KAP protein bearing three copies of the HA epitope tag at its N
terminus (HA-KAP). At 48 hr posttransfection, cells were metabol-
ically labeled with [35SSmethionine. Proteins were immunoprecipi-
tated from cell extracts by using antibodies directed against the HA
epitope (aHA), human cdc2 (acdc2), or human CDK2 (aCDK2), and
precipitated proteins were analyzed by electrophoresis. For refer-
ence, positions of protein markers (kDa) electrophoresed in parallel
are shown. Positions of the epitope-tagged KAP protein (HA-KAP),
cdc2, and CDK2 are indicated. (B) CDK2, cdc2, and KAP-associated
p34 were electrophoretically purified from immunoprecipitates sim-
ilar to those shown in A. These polypeptides were then subjected to
partial V8 protease digestion with the indicated amounts of enzyme.
Resulting peptide fragments were fractionated on a 17.5% polyacryl-
amide gel.
43
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FIG. 5. KAP associates with CDK2 in mammalian cells. Lysates
were prepared from COS cells transfected with a plasmid directing
the expression of HA-KAP and from an untransfected control.
Proteins present in anti-HA (a-HA) immunoprecipitates from each of
these cell extracts (as indicated) were electrophoresed on a 12.5%
polyacrylamide gel, transferred to nitrocellulose, and analyzed by
Western blotting with a monospecific CDK2 antiserum. Positions of
CDK2 and ofprotein size markers (kDa) (electrophoresed in parallel)
are indicated.
68--
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one or more of these proteins might be the KAP-associated
p34. Consistent with this possibility, in anti-cdc2 immuno-
precipitates from transfected cells, we observed a doublet of
bands that comigrated with the two HA-KAP species (Fig.
4A). In addition, we detected HA-KAP by Western blotting
in similar cdc2 immunoprecipitates (unpublished results). To
definitively determine the nature of the KAP-associated p34,
the protein was excised from a polyacrylamide gel and
subjected to partial digestion with V8 protease. For compar-
ison, immunoprecipitated cdc2 and CDK2 were analyzed in
parallel. As shown in Fig. 4B, the KAP-associated p34
showed a pattern of V8 peptides that corresponded to those
generated upon V8 digestion of cdc2. The slight differences
between the V8 patterns of the KAP-associated p34 and cdc2
could result from differences in the cdc2 phosphorylation
state or could indicate that the KAP-associated p34 contains
a mixture of cdc2 and CDK2. The latter possibility is sug-
gested by the fact that when similar immunoprecipitates were
examined by Western blotting, both cdc2 and CDK2 antisera
recognized the %34-kDa protein (Fig. 5; data not shown).
Considered together, these results indicate that KAP can
associate with cdc2 and CDK2 in mammalian cells. Interest-
ingly, cyclins known to associate with cdc2 and CDK2 were
not observed in KAP-CDK complexes, suggesting that KAP
does not require the presence of a cyclin subunit for CDK
binding.
Protein phosphorylation is a central mechanism by which
the cell cycle is regulated. Phosphorylation of key substrates
by activated cyclin-dependent kinases is thought to promote
passage through cell cycle transitions (reviewed in refs. 1 and
5). These kinases are themselves regulated by phosphoryla-
tion at several sites. For example, cdc2 is subject to inhibi-
tory phosphorylation of Thr-14 and Tyr-15 and requires an
activating phosphorylation at Thr-161 (ref. 38; reviewed in
ref. 1). The conservation of these residues in other members
of the CDK family suggests that they may be similarly
regulated. Several cyclins are also phosphorylated in vivo,
but the significance of these modifications is unknown (39).
It is likely that the net level of phosphorylation of each of
these proteins is dictated by the balanced activities of protein
kinases and protein phosphatases. This has been shown to be
the case for Thr-14 and Tyr-15 of cdc2 where the overall level
of phosphorylation is controlled by the opposing activities of
the weel and mikl kinases and the dual-specificity phospha-
tase cdc25 (40). The association ofKAP with cdc2 and CDK2
suggests that KAP may play a role in cell cycle control,
probably by regulating the phosphorylation state of a CDK or
CDK-associated protein.
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